VIRO: Revenue up 173% year-over-year as losses narrow and a partnership-led model is implemented
Lesedauer weniger als 1 min
Revenue grew 173% year-over-year in H1 2026, driven by a major U.S. partner order, while operating and net losses narrowed significantly. The business is transitioning to a partnership-led model, focusing on U.S. roll-out, FDA review, and new product validation.
Original document: ViroGates A/S [VIRO] Slides Release — Aug. 21 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr